AI Generated Image
Compounded GLP-1 drugs creating concern among doctors and FDA
NewsNation • • business
Key Points:
- The FDA has issued 25 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 weight-loss drugs, which lack FDA approval and oversight.
- Compounded GLP-1 medications, such as semaglutide, may carry similar side effects to brand-name drugs like Ozempic and Wegovy but pose additional safety and effectiveness risks due to inconsistent manufacturing.
- These compounded drugs have gained popularity because they are often cheaper and more accessible during shortages of FDA-approved GLP-1 drugs, which can cost over $1,000 per month and have patent protections delaying generics until at least 2032.
- Experts, including Dr. Michael Blyumin from Stanford Medicine, advise against using compounded GLP-1 drugs due to potential safety issues and encourage patients to explore other affordable options for FDA-approved medications.
- The FDA recommends that compounded drugs be used only when FDA-approved treatments cannot meet a patient's medical needs and urges patients to get prescriptions from doctors and fill them at state-licensed pharmacies.
